Page 60 - Read Online

Koukourakis et al. J Cancer Metastasis Treat 2022;8:38 https://dx.doi.org/10.20517/2394-4722.2022.43 Page 21 of 23

68. Hiroshima Y, Fukumitsu N, Saito T, et al. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced
pancreatic cancer. Radiother Oncol 2019;136:37-43. DOI PubMed
69. Maemura K, Mataki Y, Kurahara H, et al. Comparison of proton beam radiotherapy and hyper-fractionated accelerated
chemoradiotherapy for locally advanced pancreatic cancer. Pancreatology 2017;17:833-8. DOI PubMed
70. Shinoto M, Terashima K, Suefuji H, et al. A single institutional experience of combined carbon-ion radiotherapy and chemotherapy
for unresectable locally advanced pancreatic cancer. Radiother Oncol 2018;129:333-9. DOI PubMed
71. Ghaneh P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and
adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg 2019;269:520-9. PubMed
72. Oba A, Wu YHA, Colborn KL, et al. Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal
adenocarcinoma: National Cancer Database cohort analysis. Br J Surg 2022;109:450-4. DOI PubMed
73. Kharofa J, Tsai S, Kelly T, et al. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.
Radiother Oncol 2014;113:41-6. DOI PubMed PMC
74. Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by
radiographic indicators. Cancer 2012;118:5749-56. DOI PubMed
75. Hill CS, Rosati LM, Hu C, et al. Neoadjuvant stereotactic body radiotherapy after upfront chemotherapy improves pathologic
outcomes compared with chemotherapy alone for patients with borderline resectable or locally advanced pancreatic adenocarcinoma
without increasing perioperative toxicity. Ann Surg Oncol 2022;29:2456-68. DOI PubMed PMC
76. Sherman WH, Chu K, Chabot J, et al. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and
capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma. Cancer 2015;121:673-80.
DOI PubMed
77. Eguchi H, Yamada D, Iwagami Y, et al. Prolonged neoadjuvant therapy for locally advanced pancreatic cancer. Dig Surg 2018;35:70-
6. DOI PubMed
78. Kim EJ, Ben-Josef E, Herman JM, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation
therapy in patients with pancreatic cancer. Cancer 2013;119:2692-700. DOI PubMed PMC
79. Chakraborty S, Morris MM, Bauer TW, et al. Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for
borderline resectable pancreatic cancer. Gastrointest Cancer Res 2014;7:15-22. PubMed PMC
80. Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation
for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg 2016;151:e161137.
DOI PubMed PMC
81. Fiore M, Ramella S, Valeri S, et al. Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with
borderline resectable and unresectable locally advanced pancreatic cancer. Sci Rep 2017;7:45845. DOI PubMed PMC
82. Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy
for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol 2018;4:963-9. DOI PubMed PMC
83. Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in
patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg
2018;268:215-22. DOI PubMed
84. Katz MHG, Shi Q, Meyers JP, et al. Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated
radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. JCO 2021;39:377-377.
85. Okano K, Suto H, Oshima M, et al. A prospective phase II Trial of neoadjuvant S-1 with concurrent hypofractionated radiotherapy in
patients with resectable and borderline resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol 2017;24:2777-84. DOI
PubMed
86. Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline
resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol 2020;38:1763-73. DOI
PubMed PMC
87. Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline
resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial. J Clin Oncol 2022;40:1220-30. DOI
PubMed
88. Fietkau R, Ghadimi M, Grützmann R, et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or
chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial. JCO 2022;40:4008-
4008. DOI PubMed
89. Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and
concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006;13:150-8. DOI PubMed
90. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable
adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3496-502. DOI PubMed
91. Turrini O, Viret F, Moureau-Zabotto L, et al. Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with
resectable pancreatic head adenocarcinoma: a ten-year single institution experience. Oncology 2009;76:413-9. DOI PubMed
92. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based
chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3487-95. DOI PubMed
93. Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus